Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

WPD Pharmaceuticals Inc C.WBIO

Alternate Symbol(s):  WPDPF

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.


CSE:WBIO - Post by User

Comment by suomynonaon May 05, 2020 10:21am
161 Views
Post# 30987416

RE:RE:News Release Wording Over The Top?

RE:RE:News Release Wording Over The Top?Texas cancer-focused biotech Moleculin said its shares had been placed in a temporary trading halt following notification from the SEC.

The small company, which has a market cap of about $65 million, has been making statements in a smattering of regulatory filings and press releases since March 19 suggesting its experimental drug, WP1122, was a potential candidate for use in Covid-19 and that it could expedite the regulatory approval of the treatment. Between March 18 and May 1st (when the trading suspension came into effect), the value of the company’s stock has more than doubled to $1.o7.

The suspension will terminate at 11:59 p.m. ET on May 15th, 2020. Moleculin said it believes it will be able to demonstrate the accuracy and adequacy of its public disclosures. 

suomynona wrote: Pumpty Dumpty sat on a wall... nobody making a discovery as earth shaking as purported, would have to pay for a news release.

suomynona wrote: Trading halt is not surprising; that purported news would be front page 'round the world if it weren't a little too good to be true.




<< Previous
Bullboard Posts
Next >>